First human test for new weekly diabetes shot
NCT ID NCT06439056
Summary
This early-stage study tested a new, long-acting injection called NEX-22A in 12 people with type 2 diabetes. The main goal was to see how the drug moves through the body and to check for any side effects. Participants received a single injection, and researchers monitored them closely for over a month.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.